Tag Archives: keytruda

First Patient Dosed in New Trial for Relapsed Mesothelioma

relapsed mesothelioma

Doctors in the UK have started treatment on the first patient in the trial of a new drug combination for relapsed mesothelioma. The drug is called bemcentinib. It blocks a protein encoded by the AXL gene. People with mesothelioma tend to overexpress this protein. Studies show that this extra AXL protein might help cancer cells hide from the immune system. It might also help them spread to other parts of the body.  In the new trial, patients with relapsed mesothelioma will get a combination of bemcentinib and Keytruda (pembrolizumab). Keytruda is an immunotherapy drug. Like bemcentinib, it helps make mesothelioma cells vulnerable to immune system attack.  Animal studies and tests in lung cancer patients show that bemcentinib may help immune … Continue reading First Patient Dosed in New Trial for Relapsed Mesothelioma »

Keytruda and Tumor Treating Fields: New Hope for Mesothelioma?

Keytruda and Tumor Treating Fields

There is hope that a new lung cancer trial combining Keytruda and Tumor Treating Fields could lead to a new treatment for pleural mesothelioma.  Recent studies show Keytruda (pembrolizumab) is one of the most promising immunotherapy drugs against malignant mesothelioma. Electrical device Tumor Treating Fields is only the second treatment to receive FDA approval for mesothelioma.  This summer, the manufacturers of these two treatments announced they would team up. They will test Keytruda and Tumor Treating Fields in patients with non-small cell lung cancer. The results could impact the future of mesothelioma treatment, too. Two Promising Therapies: Keytruda Keytruda is an immunotherapy drug. It blocks a protein called PD-1. Many types of cancer cells overproduce PD-1 to evade the immune … Continue reading Keytruda and Tumor Treating Fields: New Hope for Mesothelioma? »

Triple Therapy May Become New First-Line Treatment for Mesothelioma

First-Line Treatment for Mesothelioma

A combination of three powerful mesothelioma therapies could become a new first-line treatment for mesothelioma if an upcoming clinical trial is successful. The makers of the experimental immunotherapy drug ONCOS-102 announced the new clinical trial. It will enroll up to 100 mesothelioma patients from around the world.  The trial will test ONCOS-102 along with Keytruda (pembrolizumab) and standard chemotherapy. Keytruda is an immune checkpoint inhibitor. Both ONCOS-102 and Keytruda have shown some promise when combined with mesothelioma chemotherapy. Targovax hopes that the triple therapy approach will produce an even more powerful first-line treatment for mesothelioma. Clinic Trial of ONCOS-102 A first-line treatment is a treatment for mesothelioma patients who have not yet had any other therapies. Most patients start with … Continue reading Triple Therapy May Become New First-Line Treatment for Mesothelioma »

FDA Approval of Keytruda will Help Some Mesothelioma Patients

FDA Approval of Keytruda

The FDA approval of Keytruda this month may help some patients in their battle against asbestos cancer.  Keytruda is the brand name for the immunotherapy drug pembrolizumab. The FDA first approved Keytruda as a first-line treatment for metastatic non-small cell lung cancer. That initial approval came in 2017. The new FDA approval of Keytruda is for treatment of specific kinds of malignant tumors. Eligible patients must have unresectable mesothelioma and no other treatment options.  How Keytruda Fights Mesothelioma Keytruda is an immune checkpoint inhibitor. It blocks a protein called PD-L1. Mesothelioma cells use PD-L1 to avoid immune system attack. Drugs like Keytruda unmask these hiding cells and make them more vulnerable to treatment.  But not all patients with mesothelioma will … Continue reading FDA Approval of Keytruda will Help Some Mesothelioma Patients »

Rare But Dangerous Side Effects of Opdivo for Mesothelioma

side effects of Opdivo

Australian researchers are warning of some rare but deadly side effects of Opdivo (nivolumab) for pleural mesothelioma.  They have just published a case report of a mesothelioma patient on nivolumab, a drug often used to treat lung cancer. The patient developed swelling of the heart and other muscles. The swelling lasted for months, even after they stopped taking the drug.  The case report details the healthcare teams’ effort to manage these potentially lethal side effects of Opdivo. They caution that other immune checkpoint inhibitors might cause similar complications. How Opdivo Fights Mesothelioma The primary treatment for mesothelioma is chemotherapy with pemetrexed (Alimta). Eventually, most patients stop responding to chemotherapy. At that point, doctors may turn to an immunotherapy drug like … Continue reading Rare But Dangerous Side Effects of Opdivo for Mesothelioma »

Personalized Immunotherapy for Mesothelioma: New Research Sheds Lights

personalized immunotherapy for mesothelioma

New research conducted by a team of German and Austrian scientists could help make personalized immunotherapy for mesothelioma possible.  Mesothelioma is an incurable cancer caused by exposure to asbestos. Immunotherapy is one of the most promising treatment approaches.  But immunotherapy drugs like Keytruda do not work for all patients. Scientists do not know exactly why this is. The new study suggests that understanding biomarkers could lead to better outcomes through personalized immunotherapy for mesothelioma.  How Does Immunotherapy Work? Immunotherapy is a broad term that means using the patient’s own immune system to fight their cancer. There are many different types of immunotherapy. Some involve stimulating an immune response. Others involve turning off the mechanism that lets mesothelioma cells hide from … Continue reading Personalized Immunotherapy for Mesothelioma: New Research Sheds Lights »

Mesothelioma Clinical Trial Results May Be Skewed by Narrow Inclusion Criteria

mesothelioma clinical trial results

Australian researchers say too many mesothelioma clinical trial results are skewed because they do not include enough “real world” patients.   By “real world patients”, they mean those who fit the profile of the typical mesothelioma patient. The researchers say some of the most important trials limit enrollment to younger people or those with few other health problems.  They say that leaves out a lot of patients. It also makes mesothelioma clinical trial results less relevant in practice.  How Clinical Trials Work Scientists typically test proposed new mesothelioma treatments on isolated cells in a lab first. If the results look promising, they will then run tests in animals to make sure the treatment is safe.   Before a medicine receives approval for … Continue reading Mesothelioma Clinical Trial Results May Be Skewed by Narrow Inclusion Criteria »

Immunotherapy for Pleural Mesothelioma: Biomarkers Urgently Needed

immunotherapy for pleural mesothelioma

A new report says biomarkers are urgently needed to determine which patients would benefit from immunotherapy for pleural mesothelioma.  Researchers made the statement in a review of immunotherapy drugs in testing for malignant mesothelioma.  They say some of these drugs have proven to be more effective than others for asbestos cancer. But a set of biomarkers would go a long way to funneling patients into the right immunotherapy for pleural mesothelioma.  The Status of Immunotherapy for Pleural Mesothelioma Immunotherapy is believed to be the most promising up-and-coming cancer treatment. Immunotherapy treatments harness the strength of the body’s own immune response to attack cancer or help other drugs do so.  Like other types of cancer, mesothelioma cells have ways of avoiding … Continue reading Immunotherapy for Pleural Mesothelioma: Biomarkers Urgently Needed »

Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma

sarcomatoid pleural mesothelioma

Japanese doctors are reporting a remarkable response from the immunotherapy drug nivolumab in a patient with sarcomatoid pleural mesothelioma.  Sarcomatoid pleural mesothelioma is a very rare form of a rare cancer. It accounts for about 10 percent of cases of malignant mesothelioma.  This subtype is typically less responsive to standard treatments than the more common epithelioid variety. But researches at Kyushu Hospital in Fukuoka, Japan say nivolumab turned things around for their patient when the case looked hopeless.  How is Sarcomatoid Pleural Mesothelioma DIfferent? Malignant mesothelioma is a cancer of the linings around organs. Pleural mesothelioma grows on the pleural membrane that surrounds the lungs.  There are three cell subtypes of mesothelioma. The three subtypes respond differently to mesothelioma treatments. … Continue reading Immunotherapy Prompts “Remarkable Response” in Sarcomatoid Pleural Mesothelioma »

Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma

keytruda case study

Italian doctors are reporting an “impressive clinical response” in a recently published Keytruda case study. The case is encouraging news for people with advanced malignant mesothelioma.   The case involves a 45-year-old woman with metastatic pleural mesothelioma. Doctors found cancer in her chest, brain, and abdomen. Even after several kinds of chemotherapy, the patient continued to go down hill.  Finally, when it looked like the woman would not live much longer, doctors tried Keytruda (pembrolizumab). The Keytruda case study documents the patient’s amazing turnaround.  Case Looked Hopeless The 45-year old woman in the Keytruda case study first went to the doctor because of shortness of breath. Doctors found that she had pleural effusion. This is a build-up of lung fluid that … Continue reading Amazing Keytruda Case Study Offers Hope for Advanced Mesothelioma »